MYRIAD GENETICS INC (MYGN) 19.94 +0.22 (+1.12%)
19.94 +0.22 (+1.12%)
US62855J1043 - Common Stock - After market: 19.6 -0.34 (-1.71%)
Buy % Consensus
Analysts have set a mean price target of 19.25. This target is -3.45% below the current price.
MYGN was analyzed by 14 analysts. The buy percentage consensus is at 47. So analysts seem to be rather neutral about MYGN.
In the previous month the buy percentage consensus was at a similar level.
MYGN was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target
Up and Down Grades
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-01-18 | Raymond James | Upgrade | Market Perform -> Outperform |
| 2022-11-02 | SVB Leerink | Maintains | Market Perform |
| 2022-10-06 | Stephens & Co. | Initiate | Equal-Weight |
| 2022-08-05 | SVB Leerink | Maintains | Market Perform |
| 2022-05-05 | SVB Leerink | Maintains | Market Perform |
| 2022-04-19 | Goldman Sachs | Maintains | Sell |
| 2021-11-03 | SVB Leerink | Maintains | Market Perform |
| 2021-06-15 | Raymond James | Initiate | Market Perform |
| 2021-06-03 | Goldman Sachs | Initiate | Sell |
| 2021-02-24 | SVB Leerink | Maintains | Market Perform |
Analyst Ratings Stock Screener Links
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA